Who is sponsoring NCT02740777?

NCT02740777 is sponsored by Shanghai Zerun Biotechnology Co.,Ltd.

What condition does NCT02740777 study?

NCT02740777 studies Human Papillomavirus, Cervical Intraepithelial Neoplasia, Persistent Infection.

What drugs are being tested in NCT02740777?

Interventions: HPV-16/18 vaccine.

What is the status of NCT02740777?

NCT02740777 is currently COMPLETED.

Last reviewed 2023-04-12 · How we verify

Immunogenicity Study of a 2-dose Immunization Schedule of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Adolescent Females Aged 9 to 14 Years

NCT02740777 Phase 2 COMPLETED

To evaluate the immune non-inferiority, as measured by antibody responses, of a 2-dose immunization schedule (0, 6 months) of recombinant human papillomavirus virus-like particle vaccine (type 16 and 18 L1 proteins, yeast) (hereinafter referred as HPV-2 vaccine) in adolescent females aged 9 to 14 years in comparison to 3-dose immunization schedule (0, 2, 6 months) in young females aged 18 to 26 years.

Details

Lead sponsor	Shanghai Zerun Biotechnology Co.,Ltd
Phase	Phase 2
Status	COMPLETED
Enrolment	900
Start date	2016-02
Completion	2019-07

Conditions

Human Papillomavirus
Cervical Intraepithelial Neoplasia
Persistent Infection

Interventions

HPV-16/18 vaccine

Primary outcomes

HPV-16 and HPV-18 antibody titers (GMT) — one month after the final injection
Compare the HPV-16 and HPV-18 specific antibody titers (GMT) between the 2-dose immunization schedule (0, 6 months) in adolescent females aged 9 to 14 years and the 3-dose immunization schedule (0, 2, 6 months) in young females aged 18 to 26 years.

Countries

China